Xintela receives 'intention to grant' decision from European Patent Office for stem cell product XSTEM

Lund, Sweden, 29 October 2020 - Xintela announced today that the European Patent Office (EPO) has issued an "Intention to grant" decision for the patent application covering the company's stem cell product XSTEM®, consisting of integrin 10-selected mesenchymal stem cells.

Using its unique marker technology and stem cell selection method, Xintela has developed a stem cell platform, XSTEM, for stem cell-based products. The company's first focus is treatment of osteoarthritis in the knee and is preparing to start clinical studies in 2021. XSTEM is also being evaluated in a preclinical model for the treatment of ARDS (Acute Respiratory Distress Syndrome), a lung complication that affects seriously ill covid-19 patients.

The company's European patent application no. 18703531.6, covering integrin 10-selected mesenchymal stem cells, has now received an intention to grant communication from the EPO. This means the EPO will grant the patent after fulfillment of certain administrative steps. The granted patent will confer protection for Xintela's stem cell product XSTEM in Europe until 2038. In addition to product protection, the patent also protects the use of XSTEM for the prevention and treatment of degenerative joint diseases such as osteoarthritis, bone sclerosis and degenerative disc disease (DDD) as well as traumatic cartilage and bone injuries.

- This is fantastic news that adds huge value to Xintela's stem cell business. A product patent that protects the stem cell product XSTEM, combined with our own GMP production facility, secures the development and commercialization of stem cell therapies from our stem cell platform for years to come, says Xintela's CEO Evy Lundgren-Åkerlund.

This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the below contact, for publication on the 29th of October, 2020.

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela
Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cells and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.

Nerladdningsbara filer


Xintelas styrelse föreslår Lars Hedbys som ny styrelseledamot

Lund, Sverige, 12 november 2020 -Xintela AB (publ) meddelar att Lars Hedbys har accepterat rollen som styrelseledamot i bolaget. Xintelas styrelse kommer föreslå att bolagets ägare formellt utser Lars till styrelseledamot vid nästa bolagsstämma. Under tiden kommer Lars att adjungeras till kommande styrelsemöten.


Xintela Board recommends Lars Hedbys as new Board member

Lund, Sweden, 12 November 2020 -Xintela AB (publ) announces that Lars Hedbys has accepted an invitation to join the Xintela Board of Directors.  The Xintela Board will recommend that shareholders formally appoint Lars at the next shareholders meeting. In the meantime, Lars will be adjoined to future Board meetings.


Lösenpris fastställt avseende teckningsoptioner av serie TO 2 i Xintela AB, där teckningsperioden inleds den 4 november 2020

EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, I ELLER TILL AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SINGAPORE, SCHWEIZ, SYDAFRIKA, USA ELLER NÅGON ANNAN JURISDIKTION DÄR DISTRIBUTION ELLER OFFENTLIGGÖRANDE SKULLE VARA I STRID MED GÄLLANDE REGLER.

Teckningsperioden avseende de teckningsoptioner av serie TO 2 som emitterades i samband med Xintela ABs ("Xintela" eller "Bolaget") nyemission av 16 754 112 units den 15 juni 2020 och nyttjande av utökningsoption den 13 juli 2020 inleds den 4 november 2020. Lösenpris vid utnyttjande av teckningsoptioner har fastställts till 2,28 SEK.


Nulägesanalys av Xintela publicerad

Lund, Sverige, 30 oktober 2020 - Xintela meddelar att en nulägesanalys av bolaget har publicerats av Biostock, som innehåller både Biostocks egen analys och information som tillhandahållits från Xintela.


Status report of Xintela published

Lund, Sweden, 30 October 2020 - Xintela announces that a status report of the company has been published by Biostock, that contains both Biostock's own analysis and information provided by Xintela.


Xintela erhåller preliminärt godkännande av Europapatentverket för sin stamcellsprodukt XSTEM

Lund, Sverige, 29 oktober 2020 - Xintela meddelar idag att Europapatentverket (EPO) har utfärdat ett preliminärt godkännande ("Intention to grant") av patentansökan avseende bolagets stamcellsprodukt XSTEM® som består av integrin 10-selekterade mesenkymala stamceller.


Xintela receives 'intention to grant' decision from European Patent Office for stem cell product XSTEM

Lund, Sweden, 29 October 2020 - Xintela announced today that the European Patent Office (EPO) has issued an "Intention to grant" decision for the patent application covering the company's stem cell product XSTEM®, consisting of integrin 10-selected mesenchymal stem cells.


Xintela ansöker om tillstånd för vävnadsinrättning

Lund, Sverige, 28 oktober 2020 - Xintela meddelar idag att bolaget har skickat in ansökan till Läkemedelsverket om tillstånd för vävnadsinrättning för hantering av vävnader och celler inför läkemedelstillverkning.


Xintela applies for tissue establishment license

Lund, Sweden, 28 October 2020 - Xintela announces today that the company has submitted an application to the Medical Products Agency for a tissue establishment license for handling tissues and cells for manufacturing of medicinal products.


Xintelas stamceller visar lovande resultat i preklinisk ARDS studie

Lund, Sverige, 26 oktober 2020 - Xintela meddelar idag att bolagets selekterade humana stamceller XSTEM® visar en behandlande effekt på ARDS (Acute Respiratory Distress Syndrome) i den pågående prekliniska studien på grisar. ARDS är en livshotande lungkomplikation som kan drabba svårt sjuka covid-19 patienter.


Xintela's stem cells show promising results in preclinical ARDS study

Lund, Sweden, 26 October 2020 - Xintela announces today that the company's selected human stem cells XSTEM® show a therapeutic effect in ARDS (Acute Respiratory Distress Syndrome) in an ongoing preclinical study in pigs. ARDS is a life-threatening lung complication that may affect severely ill covid-19 patients.



Xintela utökar och förstärker ledningen

Lund, Sverige, 19 augusti 2020 - Xintela informerar att bolaget utökar och förstärker ledningen med Peter Ekolind som COO (Chief Operating Officer) och Thomas Areschoug som CBO (Chief Business Officer). Sven Kili som har haft en kombinerad roll som COO och CMO (Chief Medical Officer) fokuserar framåt på rollen som CMO.


Xintela expands and strengthens management team

Lund, Sweden, August 19, 2020 - Xintela announces it is expanding and strengthening its management team with Peter Ekolind as COO (Chief Operating Officer) and Thomas Areschoug as CBO (Chief Business Officer). Sven Kili, who has had a combined role as COO and CMO (Chief Medical Officer), will focus on his role as CMO.


Xintela erhåller Notice of Allowance från USPTO för kvalitetssäkring av broskcellsbaserade produkter

Lund, Sverige, 29 juli 2020 - Xintela meddelar idag att det amerikanska patentverket USPTO har utfärdat ett så kallat Notice of Allowance för bolagets patentansökan avseende kvalitetssäkring av broskceller vilket är viktigt för utveckling av broskcellsbaserade cellterapiprodukter. Notice of Allowance innebär att USPTO har för avsikt att godkänna patentansökan efter att några formella åtgärder har genomförts. När patentet godkänts kommer det vara giltigt till om med 2038.


Xintela receives Notice of Allowance from USPTO for quality assurance of chondrocyte-based products

Lund, Sweden, July 29, 2020 - Xintela today announces that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company's patent application covering quality assurance of chondrocytes (XACT), which is important for the development of chondrocyte-based cell therapy products. This Notice of Allowance means that the USPTO intends to grant the patent after certain formal steps have been completed. Once granted, the patent will be valid until 2038.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90

Om beQuoted